Global Health Updates: Innovations and Challenges in Fighting Diseases

Recent developments in health news highlight the CDC's anticipation of increased COVID-19 and RSV cases during the holidays, Pfizer's appointment of Chris Boshoff as R&D chief, and Jazz Pharmaceuticals' FDA approval for a biliary tract cancer drug. Additionally, Amgen's weight-loss drug data and Neuralink's brain chip trial feature prominently.

The U.S. CDC anticipates a rise in COVID-19 and RSV cases, attributing the trend to holiday season indoor gatherings. This comes as Pfizer appoints Chris Boshoff as R&D chief amid investor pressures for innovative drugs, following criticism of the firm's acquisition spending.

Additionally, Jazz Pharmaceuticals' biliary tract cancer treatment drug has secured FDA approval, and Novartis projects sales growth through 2028. Meanwhile, weight-loss drug data from Amgen and increased drug coverage among employers continue to make headlines.

In other health news, Elon Musk's Neuralink gains approval for a clinical trial in Canada, aiming to help paralyzed individuals control devices mentally. Collaboratively, Laekna and Eli Lilly are developing a drug for obesity that preserves muscle, marking a significant step in therapeutic advancements.

(With inputs from agencies.)